Vienna, Austria: it’s day 2 of the European Cancer Congress in Vienna (Twitter #ECC2015).

Along with 18,000+ attendees we’re looking forward to hearing about some more practice changing data.

Today in Vienna brings another busy and jam packed day at the European Cancer Conference (ECC).  We’ve already reached the point where the days blur and you have no idea which day of the week it actually is, you just follow the next fresh day in your personalised program or schedule.

So what’s in store today?

This morning brings updates on lung cancer, including the much anticipated atezolizumab results in POPLAR and BIRCH, as well as urothelial bladder cancer from the IMVigor trial. There is also a melanoma session that includes the oncolytic virus T-VEC, together with pembrolizunab and cobimetinib in separate study readouts. All this before lunch!

The afternoon promises to be equally interesting with an Immunotherapy in Cancer session that includes nivolumab, pembrolizumab plus we get our first look at a novel immunocytokine targeting CEA-IL2. A parallel session explores the science behind brain tumours with presentations on the tumour microenvironment, biomarkers and current trials.

In the meantime, the embargoes lift at 7am CEST on several studies including the atezolizumab data, which we highlight here.

Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

Posted by